Maze Therapeutics MAZE
NASDAQ MAZE
$27.02 +0.17 (+0.63%)
At close: Sep 29, 2026 · 4:00 PM EDT

Maze Therapeutics (MAZE) Debt Ratio (2026)

Updated

Maze Therapeutics' (MAZE) Debt Ratio was 0.07 for Q2 2026, down 20.8% from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Debt Ratio (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 0.24
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 0.52
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 0.42
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 0.31
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 0.00
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 0.60
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Maze Therapeutics 1.49 Bn 1.49 Bn - 0.07
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.07
Mar 31, 2026 0.09
API Access

Maze Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=MAZE&period=max&api_key=YOUR_API_KEY